APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis

In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model

(2018) Miao Zhao et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro and in vivo Evaluation of APX001A/APX001 and other Gwt1 inhibitors against Cryptococcus

(2018) Karen Joy Shaw et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Significantly improved pharmacokinetics enhances in vivo efficacy of APX001 against echinocandin and multidrug resistant Candida isolates in a mouse model of invasive candidiasis

(2018) Yanan Zhao et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris

(2018) Christopher L. Hager et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

(2018) A.J. Ullmann et al.   CLINICAL MICROBIOLOGY AND INFECTION

Triazole resistance surveillance in Aspergillus fumigatus

(2018) Agustin Resendiz Sharpe et al.   MEDICAL MYCOLOGY

Surveillance for Azole-Resistant Aspergillus fumigatus in a Centralized Diagnostic Mycology Service, London, United Kingdom, 1998–2017

(2018) Alireza Abdolrasouli et al.   Frontiers in Microbiology

Multidrug-Resistant Aspergillus fumigatus Carrying Mutations Linked to Environmental Fungicide Exposure — Three States, 2010–2017

(2018) Karlyn D. Beer et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

APX001 is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis

(2018) Teclegiorgis Gebremariam et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Voriconazole Resistance and Mortality in Invasive Aspergillosis: A Multicenter Retrospective Cohort Study

(2018) Pieter P Lestrade et al.   CLINICAL INFECTIOUS DISEASES

Azole-Resistant Aspergillosis: Epidemiology, Molecular Mechanisms, and Treatment

(2017) Anuradha Chowdhary et al.   JOURNAL OF INFECTIOUS DISEASES

The global problem of antifungal resistance: prevalence, mechanisms, and management

(2017) David S Perlin et al.   LANCET INFECTIOUS DISEASES

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

(2016) Thomas F. Patterson et al.   CLINICAL INFECTIOUS DISEASES

The anti-Aspergillusdrug pipeline: Is the glass half full or empty?: Table 1.

(2016) Nir Osherov et al.   MEDICAL MYCOLOGY

Azole Resistance inAspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?

(2015) Paul E. Verweij et al.   CLINICAL INFECTIOUS DISEASES

The Investigational Agent E1210 Is Effective in Treatment of Experimental Invasive Candidiasis Caused by Resistant Candida albicans

(2014) Nathan P. Wiederhold et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Impact ofIn VivoTriazole and Echinocandin Combination Therapy for Invasive Pulmonary Aspergillosis: Enhanced Efficacy againstCyp51Mutant Isolates

(2013) Alexander J. Lepak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Isavuconazole Pharmacodynamic Target Determination for Candida Species in anIn VivoMurine Disseminated Candidiasis Model

(2013) Alexander J. Lepak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Isavuconazole (BAL4815) Pharmacodynamic Target Determination in anIn VivoMurine Model of Invasive Pulmonary Aspergillosis against Wild-Type andcyp51Mutant Isolates of Aspergillus fumigatus

(2013) Alexander J. Lepak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A comprehensive regulatory framework to address the unmet need for new antibacterial treatments

(2013) John H Rex et al.   LANCET INFECTIOUS DISEASES

Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience

(2013) D. Neofytos et al.   Transplant Infectious Disease

Inhibiting GPI Anchor Biosynthesis in Fungi Stresses the Endoplasmic Reticulum and Enhances Immunogenicity

(2012) Catherine A. McLellan et al.   ACS Chemical Biology

The top three areas of basic research onAspergillus fumigatusin 2011

(2012) Nir Osherov   Annals of the New York Academy of Sciences

Posaconazole Pharmacodynamic Target Determination against Wild-Type andCyp51Mutant Isolates of Aspergillus fumigatus in anIn VivoModel of Invasive Pulmonary Aspergillosis

(2012) Alexander J. Lepak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivity of a Novel Broad-Spectrum Antifungal, E1210, Tested against Aspergillus spp. Determined by CLSI and EUCAST Broth Microdilution Methods

(2011) Michael A. Pfaller et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of Oral E1210, a New Broad-Spectrum Antifungal with a Novel Mechanism of Action, in Murine Models of Candidiasis, Aspergillosis, and Fusariosis

(2011) Katsura Hata et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds

(2011) Mamiko Miyazaki et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

E1210, a New Broad-Spectrum Antifungal, Suppresses Candida albicans Hyphal Growth through Inhibition of Glycosylphosphatidylinositol Biosynthesis

(2011) Nao-aki Watanabe et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activities of E1210 and Comparator Agents Tested by CLSI and EUCAST Broth Microdilution Methods against Fusarium and Scedosporium Species Identified Using Molecular Methods

(2011) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method

(2011) Michael A. Pfaller et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods

(2011) M. A. Pfaller et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Azole Resistance Profile of Amino Acid Changes in Aspergillus fumigatus CYP51A Based on Protein Homology Modeling

(2010) E. Snelders et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001–2006: Overview of the Transplant‐Associated Infection Surveillance Network (TRANSNET) Database

(2010) Dimitrios P. Kontoyiannis et al.   CLINICAL INFECTIOUS DISEASES

Acquired antifungal drug resistance inAspergillus fumigatus:epidemiology and detection

(2010) Susan Julie Howard et al.   MEDICAL MYCOLOGY

Strain-Dependent Variation in 18S Ribosomal DNA Copy Numbers in Aspergillus fumigatus

(2009) M. L. Herrera et al.   JOURNAL OF CLINICAL MICROBIOLOGY